
	Chemical structure search How to Search	Import MOLfile format is only available (V3000 format is not available) Exact match Substructure search Superstructure search Substructure or superstructure search Similarity search

Details
Related links
Search

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr

J-GLOBAL ID：201601010604491214 Update date: Apr. 13, 2025

Yamasaki Ryo

ヤマサキリョウ | Yamasaki Ryo

Clips

Affiliation and department：
Job title：准教授

Research field (2)： Neurology , Neuroscience - general

Research keywords (7)： Alzhemer's disease , Parkinson's disease , multiple sclerosis , neuropathy , amyotrophic lateral sclerosis , macrophage , microglia

Research theme for competitive and other funds (32)：

2024 - 2029 RNA 動的解析による固形腫瘍を破壊可能なGAIA-102の分化誘導機構の解明
2024 - 2028 Elucidation of inflammation regulatory mechanisms in central nervous system autoimmune diseases
2023 - 2026 ヘミチャネル阻害薬を用いたαシヌクレイン伝播阻止による多系統萎縮症の治療法開発
2023 - 2026 免疫学的視点からみた中枢性神経障害性疼痛の病態解明ならびに新規治療法開発
2024 - 2025 精神神経疾患におけるミクログリア活性化とは何か?ヒト細胞を用いた疾患横断的研究

2022 - 2025 単一細胞RNA解析による多系統萎縮症増悪性ミクログリア亜群の同定と同細胞標的療法

2022 - 2025 Detection of ALS origin with reference to calcium-binding proteins, those generate glial inflammation

2022 - 2025 What is microglial activation in neuropsychiatric disorders? A cross-disease study using human cells.

2021 - 2024 グリアコネキシン低分子量イソフォーム発現エキソソームによる脱髄炎の悪化と治療開発

2020 - 2023 A novel model of multiple sclerosis and multiple system atrophy that are differentially manifested by the time of abnormal protein expression

2020 - 2023 活性化グリア細胞制御による進行性多発性硬化症および多系統萎縮症の画期的治療法開発

2019 - 2022 Significance of and treatment against galectin-3 and p22 accompanied with glial inflamation in ALS spinal cord

2019 - 2022 Development of treatment for multiple sclerosis based on rice consumption, a newly identified environmental risk factor

2019 - 2022 Establishment of primary-progressive multiple sclerosis (PPMS)/multiple system atrophy (MSA) mice model

2019 - 2022 Misfold protein removal therapy with CCR2-positive cells from peripheral nerves in motor neuron disease

2019 - 2022 Elucidation of autoimmune mechanisms and developement of novel therapy for demyelinating diseases based on genetic and envrionmental risk factors and disease-specific anti-neural antibodies

2018 - 2021 A novel mice model of MSA by overexpression of mutant alpha-synuclein in oligodendroglia in a temporarily restrictive manner using Tet-off system

2017 - 2020 Development of new MR neurography with simultaneous T2 mapping

2017 - 2020 Elucidation of the role of glial cell in tau transmission and axonal degeneration in Alzheimer's disease and targeted therapy with glial cell

2017 - 2019 Establishment of world-premier pachymeningitis animal model and development of new therapeutic option targeting TGF-beta.

2016 - 2019 The origin of retrograde motor neuron degeneration elicited by activated microglia in pre- or early-symptomatic spinal cord tissues from human patients with amyotrophic lateral sclerosis

2016 - 2019 Development of new therapeutic options for multiple sclerosis by suppression of CNS immune system augmentation due to the malfunction of astroglia connexin

2016 - 2019 Elucidation of mechanisms for destruction and fixation of glia-syncytium in demyelinating diseases by whole-genome sequencing and immunohistochemical analysis.

2015 - 2018 Retro-element insertion polymorphism in pathogenic Th17 cells specific for multiple sclerosis and its action

2015 - 2018 Elucidation of pathomecanisms via CCR2 positive monocyte-dependent neuroprotection in the amyotrophic lateral sclerosis model mice.

2015 - 2018 Therapy for multiple sclerosis targeting gamma-delta T cells and innate immunity based on genome-wide association studies in Japanese population

2013 - 2018 Elucidasion of functional contribution of glial dysturbances in pathomechanisms of demyelinating diseases and schizophrenia and development of new therapeutic options

2014 - 2017 Extensive disruption of energy transports via glial syncytium in demyelinating diseases

2014 - 2017 Development of apomorphine therapy targeting insulin resistance in Alzheimer's disease

2013 - 2016 Complete remission induction therapy development of multiple sclerosis by selective - timed activation of the protective microglia

2013 - 2016 connexin cytopathy in the pathogenesis of demyelinating disorders

2009 - 2011 ALSに対するG-CSFの運動ニューロン保護作用の解明と髄腔内持続投与療法の開発

Show all

Papers (302)：

Keitaro Matsuo, Mitsuru Watanabe, Shogo Inamine, Toshio Matsushima, Sota Kyuragi, Yasuhiro Maeda, Ryoko Katsuki, Masahiro Ohgidani, Ryo Yamasaki, Noriko Isobe, et al. The flow cytometric analysis of depression focusing on modern-type depression and hikikomori: Exploring the link between subtypes of depression and immunological imbalances. Dialogues in clinical neuroscience. 2025. 27. 1. 13-25
Takayuki Fujii, Hiroyuki Honda, Sato Yoshidomi, Kaoru Yoshida Kashu, Ryo Yamasaki, Motoi Yoshimura, Naokazu Sasagasako, Toru Iwaki, Noriko Isobe. Plexin D1 accumulation in the spinal motor neurons of patients with amyotrophic lateral sclerosis. Journal of the neurological sciences. 2025. 472. 123483-123483
Eriko Maehara, Makiko Kido-Nakahara, Yasuyuki Fujita, Kiyoko Kato, Saki Kido, Ryo Yamasaki, Satoshi Nagata, Junji Kishimoto, Hiroko Watanabe, Eri Harada, et al. Stratum Corneum Interleukin-2 in Facial Eczema at 1-Month-Old Predicts Later Atopic Dermatitis. Allergy. 2025
Ryo Yamasaki. Neuroimmunology frontiers: Unveiling immune mechanisms in central nervous system repair and pathology. Clinical and Experimental Neuroimmunology. 2024
Jeffrey A Allen, Jie Lin, Ivana Basta, Tina Dysgaard, Christian Eggers, Jeffrey T Guptill, Kelly G Gwathmey, Channa Hewamadduma, Erik Hofman, Yessar M Hussain, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. The Lancet. Neurology. 2024. 23. 10. 1013-1024

ｍore...

MISC (273)：

飯田紘太郎, 松下拓也, 松下拓也, 永田諭, 高瀬オズデミル-エズギ, 賀集薫, 藤井敬之, 渡邉充, 眞崎勝久, 山崎亮, et al. BKチャネルは視神経脊髄炎病変アストロサイトの炎症性形質転換を抑制し神経保護的に作用する. Neuroimmunology. 2024. 29. 1
飯田紘太郎, 松下拓也, 松下拓也, 永田諭, 高瀬オズデミルエズギ, 賀集薫, 藤井敬之, 渡邉充, 眞崎勝久, 山崎亮, et al. BKチャネル(KCNMA1)がアストロサイトの炎症性変化に及ぼす影響の検討. 日本臨床免疫学会総会プログラム・抄録集. 2024. 52nd
寺師綾子, 渡邉充, 佐野仁美, 田中栄蔵, 入江剛史, 山崎亮, 磯部紀子, 寺師綾子, 渡邉充, 佐野仁美, et al. ラブリズマブ使用時に侵襲性髄膜炎菌感染症が疑われた全身型重症筋無力症の一例. Neuroinfection (Web). 2023. 28. 2
山崎亮, 白石渉, 橋本侑, 江千里, 小早川優子, 磯部紀子. 筋萎縮性側索硬化症モデルマウスにおける,末梢血マクロファージによる異常蛋白除去を介した中枢神経保護機構の解明. 日本解剖学会総会・全国学術集会講演プログラム・抄録集. 2022. 127th
岡留敏樹, 上原平, 山口高弘, 横山淳, 向野隆彦, 迎伸孝, 重藤寛史, 山崎亮. 発作間欠期てんかん性放電が機能的ネットワークに及ぼす影響. 日本神経学会学術大会プログラム・抄録集. 2021. 62nd

ｍore...

Education (2)：

2004 - 2007 Kyushu University
1994 - 2000 Kyushu University School of Medicine

Professional career (1)：

医学博士 (九州大学)

Work history (9)：

2016/07 - 現在 Kyushu University Faculty of Medical Sciences
2015/07 - 2016/06 九州大学病院神経内科講師
2012/10 - 2015/06 九州大学大学院医学研究院神経治療学寄附講座
2012/04 - 2012/09 九州大学病院神経内科助教
2010/01 - 2012/03 Cleveland Clinic Larner research institute Postdoctoral fellow

Show all

Committee career (11)：

2018 - 現在日本神経学会代議員
2017 - 現在福岡市認知症疾患医療センター副センター長
2015 - 現在日本神経免疫学会評議員
2016 - 2023 福岡県・福岡市難病相談支援センター副センター長
2023 - 日本神経治療学会評議員

Show all

Awards (9)：

2023 - 日本神経学会 2023年度日本神経学会賞(学術研究部門)
2020/09 - 日本末梢神経学会第31回日本末梢神経学会賞内科部門
2020 - 九州大学神経内科神経内科奨励賞
2018 - 日本神経免疫学会研究創世賞最優秀賞
2018 - 日本末梢神経学会第29回日本末梢神経学会賞内科部門

Show all

Association Membership(s) (13)：

日本老年医学会 , 日本認知症学会 , 日本神経治療学会 , 日本神経化学会 , 日本自律神経学会 , 日本難病医療ネットワーク学会 , 日本医学教育学会 , 日本末梢神経学会 , 日本神経科学学会 , 日本神経免疫学会 , 日本脳卒中学会 , 日本神経学会 , 日本内科学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page


	Free word	※Add the following synonyms, you can increase the number of hits.




		～